# MS DCF Valuation — Investment Banking Valuation Memo
**Date: 2026-10-02 (Friday), ~09:5x ET (verified via `TZ=America/New_York date`). Price-roll update only — no WACC rebuild, no fundamentals rebuild this run.** Checked for a rate reversal per the 10/1 rebuild's own standing flag: WebSearch this run returned the same data-quality wall every desk has hit this week (one source's "4.79% as of 9/2" is itself stale/mis-dated, nothing found independently confirms a clean settled 10/1 or 10/2 print either way) — consistent with state.md's own 10/2 ~09:38 ET note ("10yr holding ~5.2-5.3% with no clean reversal below 5%"). Per rule 4, an unconfirmed read doesn't get to unwind yesterday's rebuild: **the 10/1 WACC rebuild (Rf 5.29%) stays in effect, fair values unchanged from yesterday, only live prices roll forward.**

*Persona: VP-level valuation coverage for the "Claude Robinhood Trader" experiment. Coverage this run: (1) NVDA, (2) OMCL, (3) VTI, (4) VXUS, (5) XLE, (6) GEHC — the six current holdings per state.md's 2026-10-02 ~09:38 ET live Robinhood snapshot (NVDA $235.89, VTI $378.6049, VXUS $85.165, OMCL $33.61, XLE $62.35, GEHC $64.17) — plus (7) MU, GS's current #1 screen pick (not held, unchanged rank, now confirmed inside GS's own $900-950 pullback zone at $935.93). No live Robinhood access on this desk; per rule 4, state.md's live-verified prices take precedence over WebSearch for the six holdings.*

---

## Verdicts (top line) — same fair values as 10/1's rebuild, prices roll forward

| Ticker | Current Price (10/2) | Fair Value (unchanged, 10/1 rebuild) | Gap | Verdict |
|---|---|---|---|---|
| **MU** (not held, GS #1) | $935.93 (WebSearch, matches GS's 10/2 single-source read) | $654/sh (WACC 12.59%) | **-30.1%** | **OVERVALUED — hard pass confirmed, narrower than yesterday's -38.0% purely because the stock pulled back into GS's own $900-950 zone, not because the model moved** |
| **GEHC** | $64.17 | $63.9/sh (WACC 9.09%) | **-0.4%** | **Essentially at parity — technically still the "flipped" side, but now inside model noise; see flag below** |
| **NVDA** | $235.89 | $192.0 (WACC 11.59%) | **-18.6%** | **OVERVALUED, widest reading yet** — price kept climbing while fair value didn't move |
| **XLE** | $62.35 | $58.9 (WACC 11.09%) | **-5.5%** | **OVERVALUED**, slightly wider than 10/1's -4.2% on a small price pop |
| **OMCL** | $33.61 | $49.1 (WACC 9.59%) | **+46.1%** | **UNDERVALUED — still the widest mispricing on the book by a wide margin** |
| **VTI** | $378.6049 | N/A | N/A | **HOLD BY CONSTRUCTION** |
| **VXUS** | $85.165 | N/A | N/A | **HOLD BY CONSTRUCTION** |

**Bottom line for the trader — read this first:** nothing changed in any model today. This is a pure mechanical price roll against yesterday's rebuilt fair values (same WACCs, same cash-flow builds — see 10/1 report, git history, for full methodology). Two things worth flagging on top of that mechanical roll:

1. **GEHC is now a coin-flip call, not a clean flip.** Yesterday's -2.3% gap narrowed to -0.4% simply because GEHC's price pulled back slightly ($65.42 → $64.17) while fair value held at $63.9. A gap this thin on a single-stage perpetuity model is noise, not signal — this desk is **not** calling GEHC "back to undervalued," but the "overvalued" framing from yesterday is now barely distinguishable from fair value. Treat GEHC as valuation-neutral until either the rate moves cleanly or a fresh fundamentals catalyst arrives (next print ~10/28-10/29, per JPM/GS).
2. **MU hit GS's own $900-950 technical pullback zone today ($935.93) — this desk's hard pass still fully applies.** The gap narrowed from -38.0% to -30.1% purely because the price came down, not because the valuation case improved. A -30% DCF gap is still a clear, unambiguous overvaluation call; per rule 5, a technical zone being "reached" on a name this far above intrinsic value is not a buy signal.

No trade recommended off this report (research-only mandate, as always).

---

## Per-name detail (brief — full builds unchanged, see 10/1 report for methodology)

### 1. GE HealthCare (GEHC) — flip narrows to parity
Fair value $63.9 (WACC 9.09%, unchanged). Price $64.17 (was $65.42). Gap = (63.9 − 64.17) / 64.17 = **-0.42%**. Verdict: **valuation-neutral** — no longer a meaningful overvaluation call, but no basis to call it undervalued either. Revenue/margin/FCF build unchanged since 9/23. Next earnings confirmed 10/29 (per GS's 10/2 report), ~27 days out — outside any near-term catalyst window.

### 2. NVIDIA (NVDA) — widest overvaluation on file
Fair value $192.0 (WACC 11.59%, unchanged). Price $235.89 (was $230.51). Gap = (192.0 − 235.89) / 235.89 = **-18.61%**, the widest reading this desk has ever had on NVDA, driven entirely by the price continuing to climb (+2.3% day-over-day) against an unmoved fair value. Hold, no add, no trim — gain/loss and price drift alone are not triggers (rule 1); BR's 10/1 standing instruction (no new cash to NVDA until the pool-weight overshoot closes) already addresses the sizing side.

### 3. Omnicell (OMCL) — unchanged, still the book's deepest discount
Fair value $49.1 (WACC 9.59%, unchanged). Price $33.61 (was $34.20). Gap = (49.1 − 33.61) / 33.61 = **+46.08%**, widening slightly on a small price pullback. No fresh OMCL catalyst; DCA gate (rule 18) remains the operative timing mechanism, not this desk's valuation call.

### 4. Vanguard Total Stock Market ETF (VTI) — unchanged
No single-company DCF applies. $378.6049. Defers to BR/BW on sizing and drift-band status.

### 5. Vanguard Total International Stock ETF (VXUS) — unchanged
No single-company DCF applies. $85.165. No fair-value case to add or trim.

### 6. Energy Select Sector SPDR (XLE) — overvaluation widens slightly
Fair value $58.9 (WACC 11.09%, Brent $76/bbl base case, unchanged). Price $62.35 (was $61.49). Gap = (58.9 − 62.35) / 62.35 = **-5.53%**, slightly wider than 10/1's -4.2% on a small price pop — consistent with BW's repeatedly-flagged hedge-decoupling pattern (XLE's price action still not tracking its own oil thesis cleanly). No change to the underlying composite model.

### 7. Micron (MU) — GS's #1 pick, not held — hard pass confirmed, zone reached
Fair value $654/sh (WACC 12.59%, g=3%, unchanged — see 10/1 report for the full FY27-31 build). Price $935.93 (WebSearch, single-source but now matching GS's own 10/2 read exactly, and down from the 10/1 state.md reference of ~$1,054.97). Gap = (654 − 935.93) / 935.93 = **-30.13% overvalued**. This is the most decision-relevant line in today's update: **GS flagged this morning that MU has reached its own $900-950 "actionable" pullback zone — it has, and this desk's answer is still no.** A -30% DCF gap closing in from -38% because the stock sold off is the model doing exactly what it's supposed to do (price moving toward fair value is good news for the thesis eventually working, bad news for buying today) — it is not remotely close to a buy signal yet. Not investable at current levels.

---

## Cross-check with GS screener (analysts/gs-stock-screener.md, 2026-10-02 report)

Full agreement on MU: GS explicitly frames the zone-hit as "fired... but the right action is still don't touch it," identical to this desk's own conclusion, now reached from two independent frameworks (relative-multiple screen vs. intrinsic-value build). GS's GEHC framing ("still hold, no add, no change," rate-driven DCF flip acknowledged) is consistent with this desk's parity read — GS already flagged that this desk's prior -2.3% read "still stands," which this update narrows further toward neutral rather than reversing. No disagreement on NVDA or OMCL direction. GS's priority ask (MRVL cross-vetting ahead of its 10/6 analyst day) is noted — this desk has no MRVL model yet (rule 6 gate not opened); if GS wants a DCF built ahead of 10/6, that needs to be requested explicitly with enough lead time for a full fundamentals build, not a price roll.

## Explicit read on trader's current positions (all six held) plus GS's #1 pick

**GEHC**: valuation-neutral, gap ≈ -0.4% (was -2.3%) — no longer a meaningful overvaluation call, still no basis for undervalued either; hold.
**XLE**: overvalued, gap ≈ -5.5% (was -4.2%) — hold, no add, hedge-decoupling pattern persists.
**NVDA**: overvalued, gap ≈ -18.6% (was -16.7%), widest on file — hold, no add, no trim; BR's no-new-cash instruction stands.
**OMCL**: undervalued, gap ≈ +46.1% (was +43.5%) — still the widest mispricing on the book; DCA gate unaffected.
**VTI / VXUS**: hold, no valuation view — defer to BR/BW.
**MU** (GS's #1 pick, not held): hard pass confirmed, gap ≈ -30.1% (was -38.0%, narrowed entirely by the price pullback into GS's own technical zone). Not investable.

**Standing flag for the next run, unchanged from 10/1:** this desk's models are still conditioned on the 10/1 WACC rebuild (Rf 5.29%) holding. GEHC and XLE are the first things to re-check on any confirmed rate move in either direction (their gaps are thin enough to flip again); NVDA and OMCL's verdicts are robust to a partial reversal. The next full rebuild should be triggered by either (a) a clean, independently-confirmed reversal of the 10yr below 5% sustained for a comparable period, or (b) a company-specific catalyst (earnings, guidance, M&A) on any individual name, whichever comes first — GEHC's 10/29 print is the nearest such date on the book.

---

Sources:
- [Current share price for MU — InvestSmart](https://www.investsmart.com.au/security/nasdaq/mu/micron-technology/share-price)
- [10 Year Treasury Rate — YCharts](https://ycharts.com/indicators/10_year_treasury_rate)
- [GE HealthCare announces cash dividend increase for third quarter of 2026 — Finviz](https://finviz.com/news/394504/ge-healthcare-announces-cash-dividend-increase-for-third-quarter-of-2026)
- [GEHC Q2 deep dive — Barchart](https://www.barchart.com/story/news/3554030/gehc-q2-deep-dive-product-innovation-and-service-strength-propel-growth-amid-pcs-challenges)
- Internal: trading-experiment/state.md (Balance history through 10/2 ~09:38 ET), analysts/gs-stock-screener.md (10/2 ~09:43 ET report), this desk's own 10/1 report (git history) for the full WACC-rebuild methodology and all per-name FCF builds
